Found: 4 articles
Article | Edition |
---|---|
Romashkina N.V., Klishina M.V., Carabina E.V.
Frequency and spectrum of PIK3CA mutations in hormone-dependent HER2-negative breast cancer: a single-center experience
|
№4 / 2024 |
R.V. Orlova, M.I. Gluzman, A.A. Vakhitova
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice
|
№11 / 2023 |
V.F. Semiglazov, P.V. Krivorotko, A.V. Komyakhov, T.Yu. Semiglazova, L.P. Gigolaeva, T.T. Tabagua, M.D. Kazantseva, A.P. Tergoeva, D.G. Ulrikh, M.V. Chervyak, V.V. Klimenko, N.S. Amirov, E.K. Zhiltsova, V.V. Semiglazov
The role of alpelisib in the treatment of PIK3CA – a mutated breast cancer
|
№11-12 / 2022 |
O.O. Gordeeva (1), I.P. Ganshina (1), V.I. Garifullina (2)
Dermatological toxity of alpelisib: clinical experience and review of current guidelines
|
№7 / 2021 |